Active Ingredient History
Niraparib (MK-4827) displays excellent PARP 1 and 2 inhibition. Inhibition of PARP in the context of defects in other DNA repair mechanisms provide a tumor specific way to kill cancer cells. Niraparib is in development with TESARO, under licence from Merck & Co, for the treatment of cancers (ovarian, fallopian tube and peritoneal cancer, breast cancer, prostate cancer and Ewing's sarcoma). Niraparib was characterized in a number of preclinical models before moving to phase I clinical trials, where it showed excellent human pharmacokinetics suitable for once a day oral dosing, achieved its pharmacodynamic target for PARP inhibition, and had promising activity in cancer patients. It is currently being tested in phase 3 clinical trials as maintenance therapy in ovarian cancer and as a treatment for breast cancer. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Combination drugs
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Adenocarcinoma (Phase 2)
Adnexal Diseases (Phase 2)
Angiogenesis Modulating Agents (Phase 2)
Antineoplastic Agents (Phase 2)
Astrocytoma (Phase 2)
Bevacizumab (Phase 2)
Biliary Tract Neoplasms (Phase 2)
Brain Neoplasms (Phase 2)
BRCA1 Protein (Phase 3)
Breast Neoplasms (Phase 3)
Carcinoma (Phase 2)
Carcinoma, Neuroendocrine (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 3)
Carcinoma, Ovarian Epithelial (Phase 4)
Carcinoma, Renal Cell (Phase 2)
Carcinoma, Transitional Cell (Phase 2)
Cholangiocarcinoma (Phase 2)
Colorectal Neoplasms (Phase 2)
Drug Therapy (Phase 2)
Endocrine Gland Neoplasms (Phase 2)
Endocrine System Diseases (Phase 2)
Endometrial Neoplasms (Phase 2/Phase 3)
Enzyme Inhibitors (Phase 2)
Esophageal Neoplasms (Phase 2)
Fallopian Tube Neoplasms (Phase 3)
Genital Diseases, Female (Phase 2)
Genital Neoplasms, Female (Phase 2)
Glioblastoma (Phase 2)
Glioma (Phase 2)
Gonadal Disorders (Phase 2)
Hamartoma (Phase 3)
Head and Neck Neoplasms (Phase 2)
Homologous Recombination (Phase 2)
Leiomyosarcoma (Phase 2)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1)
Leukemia, Prolymphocytic, T-Cell (Phase 1)
Liver Diseases (Phase 1)
Lung Neoplasms (Phase 2)
Lymphoma (Phase 2)
Lymphoma, Mantle-Cell (Phase 2)
Melanoma (Phase 2)
Mesothelioma (Phase 2)
Mesothelioma, Malignant (Phase 2)
Microsatellite Instability (Phase 2)
Mutation (Phase 3)
Nasopharyngeal Carcinoma (Phase 2)
Neoadjuvant Therapy (Phase 2)
Neoplasm Metastasis (Phase 2)
Neoplasms ()
Neoplasms by Histologic Type (Phase 2)
Neoplasms by Site (Phase 2)
Neoplasms, Glandular and Epithelial (Phase 2)
Ovarian Diseases (Phase 2/Phase 3)
Ovarian Neoplasms (Phase 4)
Pancreatic Neoplasms (Phase 2)
Penile Neoplasms (Phase 2)
Peritoneal Neoplasms (Phase 3)
Prostatic Neoplasms (Phase 2)
ras Proteins (Phase 2)
Rectal Neoplasms (Phase 1/Phase 2)
Retroperitoneal Neoplasms (Phase 2)
Sarcoma (Phase 2)
Sarcoma, Ewing (Phase 1)
Small Cell Lung Carcinoma (Phase 3)
Squamous Cell Carcinoma of Head and Neck (Phase 2)
Stomach Neoplasms (Phase 2)
Survival (Phase 2)
Treatment Outcome (Phase 2)
Triple Negative Breast Neoplasms (Phase 2)
Urinary Bladder Neoplasms (Phase 1/Phase 2)
Urogenital Neoplasms (Phase 2)
Urologic Neoplasms (Phase 2)
Uterine Cervical Neoplasms (Phase 2)
Uterine Neoplasms (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
